Riskpilot← Back to searchSign inGet full accessNOLabs AB
ABIn liquidationOrg 5566718853Research and experimental development on natural sciences and engineering · NACE 7210Est. 20040 employees
Revenue 2023
SEK 0
EBITDA margin
—
-105% vs 2022
Equity ratio
63.8%
Financial strength
Net profit 2023
SEK -29K
-105% vs 2022
| Revenue | SEK 0 | — |
| EBITDA | SEK -29K | -105% |
| Net profit | SEK -29K | -105% |
| Total assets | SEK 116K | -17% |
| Equity | SEK 74K | -28% |
| Employees | 0 | — |
Legal name
NOLabs AB
Org number
5566718853
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
7 december 2004
Share capital
SEK 152 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Bolaget skall bedriva utveckling, tillverkning och marknadsföring av farmaceutiska preparat och medicinsk teknologi ävensom idka därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −13 | −22 | 747 | 585 | −29 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −13 | −22 | 747 | 585 | −29 |
| Net financials | 2 | −8 | 5 | 9 | 1 |
| Profit before tax | −11 | −26 | 751 | 595 | −29 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −11 | −26 | 751 | 595 | −29 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Total assets | 178 | 170 | 190 | 139 | 116 |
| Equity | 134 | 108 | 109 | 103 | 74 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 44 | 63 | 81 | 36 | 42 |
| Total debt | 44 | 63 | 81 | 36 | 42 |
EBITDA margin
-2900000.0%
This company
15.8%
Market median
-18354530% vs market
20192023
Equity ratio
63.8%
This company
38.2%
Market median
+67% vs market
20192023
Return on equity
-39.2%
This company
18.4%
Market median
-313% vs market
20192023
Net profit margin
-2900000.0%
This company
8.1%
Market median
-35802569% vs market
20192023
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20192023
Debt / equity
0.57×
This company
0.62×
Market median
+8% vs market
20192023
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
CT Audit | Audit | 2022 |
PH Liquidator | Liquidator | 2024 |
| Name | Role | Member since |
|---|---|---|
| Former (3) | ||
| Board of Directors | 2022 – 2024 | |
| Chairman | 2022 – 2024 | |
| Deputy Board Member | 2022 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
INTERLINK INVESTMENTS LTD
NOLabs AB (this company)Board members of NOLabs AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl Teddie Leidhem | Audit | 0 companies |
| Pär Håkan Broomé | Liquidator | 0 companies |
| Ulf Peter Ahrnstein | Board of Directors | 0 companies |
| Tor Leif Peters | Chairman | 0 companies |
| Dan Leif Peters | Deputy Board Member | 0 companies |